drugset
drugset / Trial / NCT01849783

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

NCT01849783 ↗

Phase 2 Completed 41 enrolled Margarida Magalhaes-Silverman National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial investigates whether patients greater than or equal to 65 years of age diagnosed with myeloma or another plasma cell malignancy will have better outcomes with transplant followed by maintenance therapy, as primarily measured by progression-free survival, versus non-transplant approaches.

Timeline

Start
2013-04-04
Primary completion
2020-09-30
Completion
2020-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule — Intravenous
Subject Cisplatin Other / unclassified — Intravenous
Subject Cyclophosphamide Other / unclassified — Intravenous
Subject Dexamethasone Small molecule — Oral
Subject Doxorubicin Other / unclassified — Intravenous
Subject Etoposide Small molecule — Intravenous
Subject Melphalan Small molecule — Intravenous
Subject Thalidomide Other / unclassified — Oral

Indications

extramedullary plasmacytoma light chain deposition disease plasma cell myeloma primary systemic amyloidosis solitary osseous plasmacytoma